Display options
Cite
Duthie MS, Balagon MF. Combination chemoprophylaxis and immunoprophylaxis in reducing the incidence of leprosy. Risk Manag Healthc Policy. 2016;9:43-53doi: 10.2147/RMHP.S76058.
Duthie, M. S., & Balagon, M. F. (2016). Combination chemoprophylaxis and immunoprophylaxis in reducing the incidence of leprosy. Risk management and healthcare policy, 943-53. https://doi.org/10.2147/RMHP.S76058
Duthie, Malcolm S, and Balagon, Marivic F. "Combination chemoprophylaxis and immunoprophylaxis in reducing the incidence of leprosy." Risk management and healthcare policy vol. 9 (2016): 43-53. doi: https://doi.org/10.2147/RMHP.S76058
Duthie MS, Balagon MF. Combination chemoprophylaxis and immunoprophylaxis in reducing the incidence of leprosy. Risk Manag Healthc Policy. 2016 Apr 27;9:43-53. doi: 10.2147/RMHP.S76058. eCollection 2016. PMID: 27175099; PMCID: PMC4854245.
Copy Download .nbib Format: NLM
Share it on

Risk Manag Healthc Policy. 2016 Apr 27;9:43-53. doi: 10.2147/RMHP.S76058. eCollection 2016.

Combination chemoprophylaxis and immunoprophylaxis in reducing the incidence of leprosy.

Risk management and healthcare policy

Malcolm S Duthie, Marivic F Balagon

Affiliations

  1. Infectious Disease Research Institute, Seattle, WA, USA.
  2. Cebu Skin Clinic, Leonard Wood Memorial Center for Leprosy Research, Cebu City, the Philippines.

PMID: 27175099 PMCID: PMC4854245 DOI: 10.2147/RMHP.S76058

Abstract

Leprosy is a complex infectious disease caused by Mycobacterium leprae that is a leading cause of nontraumatic peripheral neuropathy. Current control strategies, with a goal of early diagnosis and treatment in the form of multidrug therapy, have maintained new case reports at ~225,000 per year. Diagnostic capabilities are limited and even with revisions to multidrug therapy regimen, treatment can still require up to a year of daily drug intake. Although alternate chemotherapies or adjunct immune therapies that could provide shorter or simpler treatment regimen appear possible, only a limited number of trials have been conducted. More proactive strategies appear necessary in the drive to elimination. As a prevention strategy, most chemoprophylaxis campaigns to date have provided about a 2-year protective window. Vaccination, in the form of a single bacillus Calmette-Guérin (BCG) immunization, generally provides ~50% reduction in leprosy cases. Adapting control strategies to provide both chemoprophylaxis and immunoprophylaxis has distinct appeal, with chemoprophylaxis theoretically buttressed by vaccination to generate immediate protection that can be sustained in the long term. We also discuss simple assays measuring biomarkers as surrogates for disease development or replacements for invasive, but not particularly sensitive, direct measures of M. leprae infection. Such assays could facilitate the clinical trials required to develop these new chemoprophylaxis, immunoprophylaxis strategies, and transition into wider use.

Keywords: T-cell; antibiotics; mycobacteria; prevention Hansen’s disease; treatment; vaccine

References

  1. Lepr Rev. 2000 Dec;71 Suppl:S37-40; discussion S40-1 - PubMed
  2. Expert Rev Vaccines. 2010 Feb;9(2):209-22 - PubMed
  3. Int J Lepr Other Mycobact Dis. 1999 Dec;67(4 Suppl):S23-5 - PubMed
  4. BMJ. 2008 Apr 5;336(7647):761-4 - PubMed
  5. Vaccine. 2007 Sep 28;25(39-40):6842-4 - PubMed
  6. Lepr Rev. 1974 Jun;45(2):104-11 - PubMed
  7. Lepr Rev. 2007 Dec;78(4):343-52 - PubMed
  8. Antimicrob Agents Chemother. 2000 Oct;44(10 ):2919-21 - PubMed
  9. J Med Microbiol. 1977 Feb;10(1):63-8 - PubMed
  10. Antimicrob Agents Chemother. 2006 Apr;50(4):1558-60 - PubMed
  11. Lepr Rev. 2010 Mar;81(1):27-33 - PubMed
  12. Lepr Rev. 2013 Mar;84(1):85-91 - PubMed
  13. J Pediatr (Rio J). 2006 Jul;82(3 Suppl):S45-54 - PubMed
  14. Lepr Rev. 2015 Mar;86(1):6-20 - PubMed
  15. Int J Lepr Other Mycobact Dis. 1993 Mar;61(1):29-34 - PubMed
  16. Int J Lepr Other Mycobact Dis. 2005 Jun;73(2):105-14 - PubMed
  17. J Dermatol. 1993 Jan;20(1):16-20 - PubMed
  18. Trans R Soc Trop Med Hyg. 2008 Jul;102(7):631-8 - PubMed
  19. Appl Microbiol Biotechnol. 2016 Apr;100(7):3267-75 - PubMed
  20. Lepr Rev. 2010 Sep;81(3):228-75 - PubMed
  21. Int J Lepr Other Mycobact Dis. 1987 Dec;55(4):633-6 - PubMed
  22. Lepr Rev. 2000 Dec;71 Suppl:S21-3; discussion S24-5 - PubMed
  23. Infect Immun. 1994 Oct;62(10):4250-5 - PubMed
  24. Acta Leprol. 1991;7(4):321-6 - PubMed
  25. Int J Lepr Other Mycobact Dis. 1989 Dec;57(4):735-43 - PubMed
  26. Lepr India. 1977 Jul;49(3):387-92 - PubMed
  27. Clin Infect Dis. 2002 Jan 1;34(1):39-45 - PubMed
  28. Lepr Rev. 2000 Dec;71 Suppl:S176-81 - PubMed
  29. Int J Lepr Other Mycobact Dis. 2001 Sep;69(3):177-86 - PubMed
  30. Lepr Rev. 2011 Sep;82(3):253-8 - PubMed
  31. Int J Lepr Other Mycobact Dis. 1995 Mar;63(1):8-17 - PubMed
  32. Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1443-51 - PubMed
  33. Antimicrob Agents Chemother. 1994 Mar;38(3):515-7 - PubMed
  34. Int J Lepr Other Mycobact Dis. 2003 Dec;71(4):308-19 - PubMed
  35. J Infect Dis. 2006 Feb 1;193(3):346-53 - PubMed
  36. Infect Immun. 2014 Sep;82(9):3979-85 - PubMed
  37. PLoS Negl Trop Dis. 2008 Feb 13;2(2):e167 - PubMed
  38. Antimicrob Agents Chemother. 1994 Apr;38(4):662-7 - PubMed
  39. Indian J Lepr. 1998 Oct-Dec;70(4):369-88 - PubMed
  40. Psychol Health Med. 2006 Aug;11(3):367-73 - PubMed
  41. Int J Lepr Other Mycobact Dis. 1990 Jun;58(2):281-95 - PubMed
  42. Clin Vaccine Immunol. 2006 Mar;13(3):333-40 - PubMed
  43. Lepr Rev. 2000 Dec;71 Suppl:S81-7 - PubMed
  44. Lancet. 1992 Feb 22;339(8791):446-50 - PubMed
  45. Wkly Epidemiol Rec. 2010 Aug 27;85(35):337-48 - PubMed
  46. Lepr Rev. 2000 Dec;71 Suppl:S33-5; discussion S35-6 - PubMed
  47. Trop Med Int Health. 2000 Jun;5(6):388-99 - PubMed
  48. Vaccine. 2000 Jan 31;18(14):1294-7 - PubMed
  49. Int J Lepr Other Mycobact Dis. 2002 Sep;70(3):182-90 - PubMed
  50. Mem Inst Oswaldo Cruz. 2012 Dec;107 Suppl 1:60-7 - PubMed
  51. Int J Lepr Other Mycobact Dis. 1990 Sep;58(3):503-11 - PubMed
  52. Am J Trop Med Hyg. 2008 Mar;78(3):518-21 - PubMed
  53. BMJ. 2008 Apr 5;336(7647):730-1 - PubMed
  54. Int J Lepr Other Mycobact Dis. 2000 Dec;68(4):452-5 - PubMed
  55. Int J Lepr Other Mycobact Dis. 2001 Mar;69(1):43-5 - PubMed
  56. Lepr Rev. 2003 Sep;74(3):196-205 - PubMed
  57. Indian J Dermatol. 2013 Mar;58(2):93-100 - PubMed
  58. Int J Lepr Other Mycobact Dis. 2004 Jun;72(2):166-8 - PubMed
  59. PLoS Negl Trop Dis. 2011 Sep;5(9):e1330 - PubMed
  60. Lepr India. 1978 Jul;50(3):334-44 - PubMed
  61. Infect Immun. 1990 Mar;58(3):711-8 - PubMed
  62. Am J Trop Med Hyg. 1974 Nov;23(6):1120-4 - PubMed
  63. Int J Lepr Other Mycobact Dis. 1989 Sep;57(3):607-14 - PubMed
  64. Lepr Rev. 2000 Jun;71(2):144-53 - PubMed
  65. Cell Immunol. 2005 Jan;233(1):53-60 - PubMed
  66. Int J Lepr Other Mycobact Dis. 1993 Mar;61(1):35-43 - PubMed
  67. Nature. 2001 Feb 22;409(6823):1007-11 - PubMed
  68. Wkly Epidemiol Rec. 1995 Aug 11;70(32):229-31 - PubMed
  69. Clin Vaccine Immunol. 2007 Nov;14(11):1400-8 - PubMed
  70. Infect Immun. 2003 Mar;71(3):1596-8 - PubMed
  71. Dermatol Clin. 2008 Apr;26(2):221-9, vi - PubMed
  72. Clin Vaccine Immunol. 2008 Nov;15(11):1659-65 - PubMed
  73. Int J Lepr Other Mycobact Dis. 1995 Jun;63(2):259-64 - PubMed
  74. Vaccine. 1999 Dec 10;18(9-10):795-8 - PubMed
  75. Lepr Rev. 1963 Apr;34:57-61 - PubMed
  76. BMC Infect Dis. 2013 Oct 23;13:497 - PubMed
  77. Lepr Rev. 2002 Dec;73(4):366-75 - PubMed
  78. J Infect. 2000 Sep;41(2):137-42 - PubMed
  79. BMC Infect Dis. 2013 Oct 03;13:456 - PubMed
  80. Antimicrob Agents Chemother. 1997 Sep;41(9):1953-6 - PubMed
  81. Mem Inst Oswaldo Cruz. 2012 Dec;107 Suppl 1:104-11 - PubMed
  82. Diagn Microbiol Infect Dis. 2014 Jun;79(2):233-9 - PubMed
  83. J Infect. 2005 Jan;50(1):6-11 - PubMed
  84. Lepr Rev. 1973 Mar;44(1):33-5 - PubMed
  85. Eur J Clin Microbiol Infect Dis. 2014 Aug;33(8):1415-24 - PubMed
  86. Clin Diagn Lab Immunol. 2001 Jan;8(1):138-42 - PubMed
  87. Lancet Infect Dis. 2006 Mar;6(3):162-70 - PubMed
  88. PLoS Negl Trop Dis. 2008 Feb 27;2(2):e198 - PubMed
  89. Trop Med Int Health. 2002 Sep;7(9):780-7 - PubMed
  90. Lepr Rev. 2013 Mar;84(1):3-12 - PubMed
  91. Antimicrob Agents Chemother. 1996 Sep;40(9):2137-41 - PubMed
  92. Lepr Rev. 2004 Jun;75(2):118-30 - PubMed
  93. Wkly Epidemiol Rec. 2015 Sep 4;90(36):461-74 - PubMed
  94. Lepr Rev. 2011 Dec;82(4):402-21 - PubMed
  95. Vaccine. 2001 Feb 28;19(15-16):1906-10 - PubMed
  96. Lepr Rev. 2004 Dec;75(4):376-88 - PubMed
  97. J Clin Microbiol. 2014 Feb;52(2):613-9 - PubMed
  98. BMJ. 1992 Jan 11;304(6819):91-2 - PubMed
  99. Lepr Rev. 2006 Mar;77(1):48-61 - PubMed
  100. Int J Lepr Other Mycobact Dis. 1994 Dec;62(4):568-73 - PubMed
  101. Int J Lepr Other Mycobact Dis. 1999 Jun;67(2):164-7 - PubMed
  102. Mem Inst Oswaldo Cruz. 2012 Dec;107 Suppl 1:55-9 - PubMed
  103. Antimicrob Agents Chemother. 2001 Dec;45(12):3635-9 - PubMed
  104. Infect Immun. 2006 Nov;74(11):6264-71 - PubMed
  105. Indian J Lepr. 1988 Apr;60(2):252-9 - PubMed
  106. Am J Hyg. 1960 Mar;71:147-57 - PubMed
  107. Parasit Vectors. 2015 Oct 22;8:542 - PubMed
  108. Lancet. 1996 Jul 6;348(9019):17-24 - PubMed
  109. Diagn Microbiol Infect Dis. 2015 Oct;83(2):154-61 - PubMed
  110. Int J Lepr Other Mycobact Dis. 1999 Dec;67(4 Suppl):S26-9 - PubMed
  111. Eur J Clin Microbiol Infect Dis. 1994 Nov;13(11):942-52 - PubMed
  112. Lancet. 2005 Oct 8;366(9493):1290-5 - PubMed
  113. PLoS Negl Trop Dis. 2015 Apr 23;9(4):e0003658 - PubMed
  114. Science. 1999 May 28;284(5419):1520-3 - PubMed
  115. Am J Trop Med Hyg. 1972 Jul;21(4):446-9 - PubMed
  116. Int J Lepr Other Mycobact Dis. 1966 Jul-Sep;34(3):255-73 - PubMed
  117. Clin Vaccine Immunol. 2008 Jan;15(1):101-5 - PubMed
  118. Int J Lepr Other Mycobact Dis. 1997 Sep;65(3):320-7 - PubMed
  119. Mem Inst Oswaldo Cruz. 2012 Dec;107 Suppl 1:112-23 - PubMed
  120. Int J Lepr Other Mycobact Dis. 2004 Mar;72(1):1-7 - PubMed
  121. Int J Lepr Other Mycobact Dis. 2001 Jun;69(2):93-8 - PubMed
  122. Int J Lepr Other Mycobact Dis. 2004 Dec;72(4):493-500 - PubMed
  123. Int J Lepr Other Mycobact Dis. 2003 Sep;71(3):240-3 - PubMed
  124. PLoS Negl Trop Dis. 2008 Jan 30;2(1):e113 - PubMed
  125. Lepr Rev. 1999 Sep;70(3):287-94 - PubMed
  126. Mem Inst Oswaldo Cruz. 2012 Dec;107 Suppl 1:90-4 - PubMed
  127. Am J Trop Med Hyg. 2005 Apr;72(4):443-8 - PubMed
  128. BMC Infect Dis. 2009 May 27;9:75 - PubMed
  129. Infect Immun. 2014 Sep;82(9):3900-9 - PubMed
  130. Vaccine. 2004 Sep 9;22(27-28):3649-57 - PubMed
  131. Emerg Infect Dis. 2012 May;18(5):889-90 - PubMed
  132. Antimicrob Agents Chemother. 2006 Oct;50(10):3350-4 - PubMed
  133. Eur J Clin Microbiol Infect Dis. 2011 Oct;30(10):1257-65 - PubMed
  134. Public Health. 2005 Mar;119(3):209-16 - PubMed
  135. Vaccine. 2013 Jan 21;31(5):813-9 - PubMed
  136. Lepr Rev. 2005 Jun;76(2):127-43 - PubMed
  137. BMC Infect Dis. 2011 Jan 26;11:26 - PubMed

Publication Types